Advances in the management of renal cell carcinoma

doi:10.1503/cmaj.230356

Review

. 2024 Feb 25;196(7):E235-E240.

doi: 10.1503/cmaj.230356.

Advances in the management of renal cell carcinoma

Luisa M Cardenas¹, Samantha Sigurdson¹, Christopher J D Wallis¹, Aly-Khan Lalani², Anand Swaminath²

Affiliations

¹ Department of Oncology (Cardenas, Sigurdson, Lalani, Swaminath), Juravinski Cancer Centre, McMaster University, Hamilton, Ont.; Division of Urology, Department of Surgery (Wallis), University of Toronto; Division of Urology, Department of Surgery (Wallis), Mount Sinai Hospital; Department of Surgical Oncology (Wallis), University Health Network, Toronto, Ont.
² Department of Oncology (Cardenas, Sigurdson, Lalani, Swaminath), Juravinski Cancer Centre, McMaster University, Hamilton, Ont.; Division of Urology, Department of Surgery (Wallis), University of Toronto; Division of Urology, Department of Surgery (Wallis), Mount Sinai Hospital; Department of Surgical Oncology (Wallis), University Health Network, Toronto, Ont. swaminath@HHSC.CA lalania@hhsc.ca.

PMID: 38408783
PMCID: PMC10896601
DOI: 10.1503/cmaj.230356

Review

Advances in the management of renal cell carcinoma

Luisa M Cardenas et al. CMAJ. 2024.

. 2024 Feb 25;196(7):E235-E240.

doi: 10.1503/cmaj.230356.

Authors

Luisa M Cardenas¹, Samantha Sigurdson¹, Christopher J D Wallis¹, Aly-Khan Lalani², Anand Swaminath²

Affiliations

¹ Department of Oncology (Cardenas, Sigurdson, Lalani, Swaminath), Juravinski Cancer Centre, McMaster University, Hamilton, Ont.; Division of Urology, Department of Surgery (Wallis), University of Toronto; Division of Urology, Department of Surgery (Wallis), Mount Sinai Hospital; Department of Surgical Oncology (Wallis), University Health Network, Toronto, Ont.
² Department of Oncology (Cardenas, Sigurdson, Lalani, Swaminath), Juravinski Cancer Centre, McMaster University, Hamilton, Ont.; Division of Urology, Department of Surgery (Wallis), University of Toronto; Division of Urology, Department of Surgery (Wallis), Mount Sinai Hospital; Department of Surgical Oncology (Wallis), University Health Network, Toronto, Ont. swaminath@HHSC.CA lalania@hhsc.ca.

PMID: 38408783
PMCID: PMC10896601
DOI: 10.1503/cmaj.230356

Erratum in

Correction to "Advances in the management of renal cell carcinoma".
[No authors listed] [No authors listed] CMAJ. 2024 Oct 27;196(36):E1241. doi: 10.1503/cmaj.241508. CMAJ. 2024. PMID: 39467602 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Christopher Wallis has received consulting fees from Janssen Oncology, Nanostics, Inc., Precision Point Specialty LLC, Sesen Bio; honoraria or travel fees from AbbVie, Astellas, AstraZeneca, Bayer, EMD Serono, Haymarket Media, Healing and Cancer Foundation, Janssen, Knight Therapeutics, Merck, Science & Medicine Canada, TerSera Canada, and Tolmar Pharmaceuticals Canada; research funding from Knight Therapeutics, Tolmar Pharmaceuticals and Bayer. Aly-Khan Lalani has received honoraria and/or consultancy fees from AbbVie, Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche/Genentech and TerSera, and research funding from Bristol Myers Squibb, BioCanRx, EMD Serono, Ipsen, Novartis and Roche. Anand Swaminath has received honoraria from Bristol Myers Squibb, Eisai, and AstraZeneca, and holds a voluntary position on the medical advisory board for Kidney Cancer Canada.

Cited by

Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.
Villafuerte CJQ, Swaminath A. Villafuerte CJQ, et al. Cancers (Basel). 2024 Sep 29;16(19):3334. doi: 10.3390/cancers16193334. Cancers (Basel). 2024. PMID: 39409955 Free PMC article. Review.
Stereotactic ablative radiotherapy for primary kidney cancer - An international patterns of practice survey.
Taplin K, Hannan R, Lo SS, Morgan SC, Ali M, Sigurdson S, Guckenberger M, Swaminath A. Taplin K, et al. Clin Transl Radiat Oncol. 2024 Nov 21;50:100891. doi: 10.1016/j.ctro.2024.100891. eCollection 2025 Jan. Clin Transl Radiat Oncol. 2024. PMID: 39687770 Free PMC article.
Revealing the Mechanism of Esculin in Treating Renal Cell Carcinoma Based on Network Pharmacology and Experimental Validation.
Chen Z, Wang C, Cai Y, Xu A, Han C, Tong Y, Cheng S, Liu M. Chen Z, et al. Biomolecules. 2024 Aug 22;14(8):1043. doi: 10.3390/biom14081043. Biomolecules. 2024. PMID: 39199428 Free PMC article.
RUVBL1 in Clear-Cell Renal Cell Carcinoma: Unraveling Prognostic Significance and Correlation with HIF1A.
Durślewicz J, Wybierała AM, Szczepanek S, Antosik P, Jaworski D, Grzanka D. Durślewicz J, et al. Cancers (Basel). 2024 Mar 25;16(7):1273. doi: 10.3390/cancers16071273. Cancers (Basel). 2024. PMID: 38610951 Free PMC article.
Non-invasive prediction of nuclear grade in renal cell carcinoma using CT-Based radiomics: a systematic review and meta-analysis.
Salimi M, Hajikarimloo B, Vadipour P, Abdolizadeh A, Fayedeh F, Seifi S. Salimi M, et al. Abdom Radiol (NY). 2025 Jun 11. doi: 10.1007/s00261-025-05056-x. Online ahead of print. Abdom Radiol (NY). 2025. PMID: 40495027 Review.

See all "Cited by" articles

References

1. Brenner DR, Poirier A, Woods RR, et al. . Projected estimates of cancer in Canada in 2022. CMAJ 2022;194:E601–7. - PMC - PubMed
1. Bukavina L, Bensalah K, Bray F, et al. . Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 2022;82:529–42. - PubMed
1. Wah TM, Irving HC, Gregory W, et al. . Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014;113:416–28. - PMC - PubMed
1. Motzer RJ, McDermott DF, Escudier B, et al. . Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022;128:2085–97. - PMC - PubMed
1. Richard PO, Violette PD, Bhindi B, et al. . Canadian Urological Association guideline: Management of small renal masses: full text. Can Urol Assoc J 2022; 16: E61–75. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Brenner DR, Poirier A, Woods RR, et al. . Projected estimates of cancer in Canada in 2022. CMAJ 2022;194:E601–7. - PMC - PubMed

[2] Brenner DR, Poirier A, Woods RR, et al. . Projected estimates of cancer in Canada in 2022. CMAJ 2022;194:E601–7. - PMC - PubMed

[3] Bukavina L, Bensalah K, Bray F, et al. . Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 2022;82:529–42. - PubMed

[4] Bukavina L, Bensalah K, Bray F, et al. . Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 2022;82:529–42. - PubMed

[5] Wah TM, Irving HC, Gregory W, et al. . Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014;113:416–28. - PMC - PubMed

[6] Wah TM, Irving HC, Gregory W, et al. . Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014;113:416–28. - PMC - PubMed

[7] Motzer RJ, McDermott DF, Escudier B, et al. . Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022;128:2085–97. - PMC - PubMed

[8] Motzer RJ, McDermott DF, Escudier B, et al. . Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022;128:2085–97. - PMC - PubMed

[9] Richard PO, Violette PD, Bhindi B, et al. . Canadian Urological Association guideline: Management of small renal masses: full text. Can Urol Assoc J 2022; 16: E61–75. - PMC - PubMed

[10] Richard PO, Violette PD, Bhindi B, et al. . Canadian Urological Association guideline: Management of small renal masses: full text. Can Urol Assoc J 2022; 16: E61–75. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Advances in the management of renal cell carcinoma

Affiliations

Advances in the management of renal cell carcinoma

Authors

Affiliations

Erratum in

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Erratum in

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Medical